Pulmonary imaging after stereotactic radiotherapy-does RECIST still apply?

British Journal of Radiology

Volumn 89, Issue 1065, 2016, Pages

  Mattonen, Sarah A ^a   Ward, Aaron D ^a   Palma, David A ^a,b  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b LONDON HEALTH SCIENCES CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE F 18; RADIOPHARMACEUTICAL AGENT;

ABLATION THERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; COMPUTER ASSISTED TOMOGRAPHY; HUMAN; MEDICAL ASSESSMENT; POSITRON EMISSION TOMOGRAPHY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; STEREOTACTIC ABLATIVE RADIOTHERAPY; STEREOTACTIC BODY RADIATION THERAPY; THORAX RADIOGRAPHY; DIAGNOSTIC IMAGING; ETIOLOGY; LUNG NEOPLASMS; OBSERVER VARIATION; ONCOLOGIST; POSITRON EMISSION TOMOGRAPHY-COMPUTED TOMOGRAPHY; PROCEDURES; RADIOLOGIST; RADIOSURGERY; RESPONSE EVALUATION CRITERIA IN SOLID TUMORS; SCINTIGRAPHY; STANDARDS; TREATMENT OUTCOME; TUMOR RECURRENCE; X-RAY COMPUTED TOMOGRAPHY;

ABLATION TECHNIQUES; FLUORODEOXYGLUCOSE F18; HUMANS; LUNG NEOPLASMS; NEOPLASM RECURRENCE, LOCAL; OBSERVER VARIATION; ONCOLOGISTS; PERFUSION IMAGING; POSITRON EMISSION TOMOGRAPHY COMPUTED TOMOGRAPHY; RADIOLOGISTS; RADIOPHARMACEUTICALS; RADIOSURGERY; RESPONSE EVALUATION CRITERIA IN SOLID TUMORS; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 84989830482     PISSN: 00071285     EISSN: None     Source Type: Journal    
DOI: 10.1259/bjr.20160113     Document Type: Review

References (84)

1. Ettinger DS, Wood DE, Akerley W, Bazhenova LA, Borghaei H, Camidge DR, et al. Non-small cell lung cancer, version 1.2015. J Natl Compr Canc Netw 2014; 12: 1738-61.
2. Vansteenkiste J, De Ruysscher D, Eberhardt WE, Lim E, Senan S, Felip E, et al. Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2013; 24(Suppl. 6): vi89-98. doi: http://dx.doi.org/10.1093/annonc/mdt241
3. Corso CD, Park HS, Moreno AC, Kim AW, James BY, Husain ZA, et al. Stage I lung SBRT clinical practice patterns. Am J Clin Oncol 2014. doi: http://dx.doi.org/10.1097/COC.0000000000000162
4. Chang JY, Senan S, Paul MA, Mehran RJ, Louie AV, Balter P, et al. Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials. Lancet Oncol 2015; 16: 630-37. doi: http://dx.doi.org/10.1016/S1470-2045(15)70168-3
5. Nguyen NP, Garland L, Welsh J, Hamilton R, Cohen D, Vinh-Hung V. Can stereotactic fractionated radiation therapy become the standard of care for early stage non-small cell lung carcinoma. Cancer Treat Rev 2008; 34: 719-27. doi: http://dx.doi.org/10.1016/j. ctrv.2008.06.001
6. Senan S, Paul MA, Lagerwaard FJ. Treatment of early-stage lung cancer detected by screening: surgery or stereotactic ablative radiotherapy? Lancet Oncol 2013; 14: e270-4. doi: http://dx.doi.org/10.1016/S1470-2045 (12)70592-2
7. Louie AV, van Werkhoven E, Chen H, Smit EF, Paul MA, Widder J, et al. Patient reported outcomes following stereotactic ablative radiotherapy or surgery for stage IA non-smallcell lung cancer: results from the ROSEL multicenter randomized trial. Radiother Oncol 2015; 117: 44-8. doi: http://dx.doi.org/10.1016/j.radonc.2015.08.011
8. Pan H, Simpson DR, Mell LK, Mundt AJ, Lawson JD. A survey of stereotactic body radiotherapy use in the United States. Cancer 2011; 117: 4566-72. doi: http://dx.doi.org/10.1002/cncr.26067
9. Palma DA, Louie AV, Rodrigues GB. New strategies in stereotactic radiotherapy for oligometastases. Clin Cancer Res 2015; 21: 5198-204. doi: http://dx.doi.org/10.1158/1078-0432.CCR-15-0822
10. Alongi F, Arcangeli S, Filippi AR, Ricardi U, Scorsetti M. Review and uses of stereotactic body radiation therapy for oligometastases. Oncologist 2012; 17: 1100-7. doi: http://dx. doi.org/10.1634/theoncologist.2012-0092
11. Widder J, Klinkenberg TJ, Ubbels JF, Wiegman EM, Groen HJ, Langendijk JA. Pulmonary oligometastases: metastasectomy or stereotactic ablative radiotherapy? Radiother Oncol 2013; 107: 409-13. doi: http://dx. doi.org/10.1016/j.radonc.2013.05.024
12. Palma DA, Haasbeek CJ, Rodrigues GB, Dahele M, Lock M, Yaremko B, et al. Stereotactic ablative radiotherapy for comprehensive treatment of oligometastatic tumors (SABR-COMET): study protocol for a randomized phase II trial. BMC Cancer 2012; 12: 305. doi: http://dx.doi.org/10.1186/1471-2407-12-305
13. Huang K, Palma DA. Follow-up of patients after stereotactic radiation for lung cancer: a primer for the nonradiation oncologist. J Thorac Oncol 2015; 10: 412-19. doi: http://dx.doi.org/10.1097/JTO.0000000000000435
14. Trakul N, Harris JP, Le QT, Hara WY, Maxim PG, Loo BW Jr, et al. Stereotactic ablative radiotherapy for reirradiation of locally recurrent lung tumors. J Thorac Oncol 2012; 7: 1462-5. doi: http://dx.doi.org/10.1097/JTO.0b013e31825f22ce
15. Neri S, Takahashi Y, Terashi T, Hamakawa H, Tomii K, Katakami N, et al. Surgical treatment of local recurrence after stereotactic body radiotherapy for primary and metastatic lung cancers. J Thorac Oncol 2010; 5: 2003-7. doi: http://dx.doi.org/10.1097/JTO.0b013e3181f8a785
16. Allibhai Z, Cho B, Taremi M, Atallah S, Hope A, Hwang D, et al. Surgical salvage following stereotactic body radiotherapy for early-stage NSCLC. Eur Respir J 2012; 39: 1039-42. doi: http://dx.doi.org/10.1183/09031936.00075811
17. Senthi S, Lagerwaard FJ, Haasbeek CJ, Slotman BJ, Senan S. Patterns of disease recurrence after stereotactic ablative radiotherapy for early stage non-small-cell lung cancer: a retrospective analysis. Lancet Oncol 2012; 13: 802-9. doi: http://dx.doi.org/10.1016/S1470-2045(12)70242-5
18. Palma DA, van Sornsen de Koste J, Verbakel WF, Vincent A, Senan S. Lung density changes after stereotactic radiotherapy: a quantitative analysis in 50 patients. Int J Radiat Oncol Biol Phys 2011; 81: 974-8. doi: http://dx.doi.org/10.1016/j.ijrobp.2010.07.025
19. Senthi S, Dahele M, van de Ven PM, Slotman BJ, Senan S. Late radiologic changes after stereotactic ablative radiotherapy for early stage lung cancer: a comparison of fixedbeam versus arc delivery techniques. Radiother Oncol 2013; 109: 77-81. doi: http://dx.doi.org/10.1016/j.radonc.2013.08.034
20. Dahele M, Palma D, Lagerwaard F, Slotman B, Senan S. Radiological changes after stereotactic radiotherapy for stage I lung cancer. J Thorac Oncol 2011; 6: 1221-8. doi: http://dx.doi.org/10.1097/JTO.0b013e318219aac5
21. Palma DA, Senan S, Haasbeek CJ, Verbakel WF, Vincent A, Lagerwaard F. Radiological and clinical pneumonitis after stereotactic lung radiotherapy: a matched analysis of three-dimensional conformal and volumetric-modulated arc therapy techniques. Int J Radiat Oncol Biol Phys 2011; 80: 506-13. doi: http://dx.doi.org/10.1016/j. ijrobp.2010.02.032
22. Trovo M, Linda A, El Naqa I, Javidan-Nejad C, Bradley J. Early and late lung radiographic injury following stereotactic body radiation therapy (SBRT). Lung Cancer 2010; 69: 77-85. doi: http://dx.doi.org/10.1016/j. lungcan.2009.09.006
23. Matsuo Y, Nagata Y, Mizowaki T, Takayama K, Sakamoto T, Sakamoto M, et al. Evaluation of mass-like consolidation after stereotactic body radiation therapy for lung tumors. Int J Clin Oncol 2007; 12: 356-62. doi: http://dx.doi.org/10.1007/s10147-007-0691-9
24. Taira N, Kawabata T, Ichi T, Kushi K, Yohena T, Kawasaki H, et al. Salvage operation for late recurrence after stereotactic body radiotherapy for lung cancer: two patients with no viable cancer cells. Ann Thorac Surg 2014; 97: 2167-71. doi: http://dx.doi.org/10.1016/j. athoracsur.2013.07.123
25. Takeda A, Kunieda E, Takeda T, Tanaka M, Sanuki N, Fujii H, et al. Possible misinterpretation of demarcated solid patterns of radiation fibrosis on CT scans as tumor recurrence in patients receiving hypofractionated stereotactic radiotherapy for lung cancer. Int J Radiat Oncol Biol Phys 2008; 70: 1057-65. doi: http://dx.doi.org/10.1016/j. ijrobp.2007.07.2383
26. Stauder MC, Rooney JW, Neben-Wittich MA, Garces YI, Olivier KR. Late tumor pseudoprogression followed by complete remission after lung stereotactic ablative radiotherapy. Radiat Oncol 2013; 8: 167. doi: http://dx.doi.org/10.1186/1748-717X-8-167
27. Takenaka R, Shibamoto Y, Miyakawa A, Hashizume C, Baba F. The fate of residual tumor masses that persist after stereotactic body radiotherapy for solitary lung nodules: will they recur? Clin Lung Cancer 2015. doi: http://dx.doi.org/10.1016/j.cllc.2015.12.003
28. Timmerman R, Hu C, Michalski J, Straube W, Galvin J, Johnstone D, et al. Long-term results of RTOG 0236: a phase II trial of stereotactic body radiation therapy (SBRT) in the treatment of patients with medically inoperable stage I non-small cell lung cancer. Int J Radiat Oncol Biol Phys 2014; 1: S30. doi: http://dx.doi.org/10.1016/j.ijrobp.2014. 05.135
29. Timmerman R, Paulus R, Galvin J, Michalski J, Straube W, Bradley J, et al. Stereotactic body radiation therapy for inoperable early stage lung cancer. JAMA 2010; 303: 1070-6. doi: http://dx.doi.org/10.1001/jama.2010.261
30. Chen F, Matsuo Y, Yoshizawa A, Sato T, Sakai H, Bando T, et al. Salvage lung resection for non-small cell lung cancer after stereotactic body radiotherapy in initially operable patients. J Thorac Oncol 2010; 5: 1999-2002. doi: http://dx.doi.org/10.1097/JTO. 0b013e3181f260f9
31. Shirata Y, Jingu K, Koto M, Kubozono M, Takeda K, Sugawara T, et al. Prognostic factors for local control of stage I non-small cell lung cancer in stereotactic radiotherapy: a retrospective analysis. Radiat Oncol 2012; 7: 182. doi: http://dx.doi.org/10.1186/1748-717X-7-182
32. Woody NM, Stephans KL, Marwaha G, Djemil T, Videtic GM. Stereotactic body radiation therapy for non-small cell lung cancer tumors greater than 5 cm: safety and efficacy. Int J Radiat Oncol Biol Phys 2015; 92: 325-31. doi: http://dx.doi.org/10.1016/j. ijrobp.2015.01.045
33. Matsuo Y, Shibuya K, Nagata Y, Takayama K, Norihisa Y, Mizowaki T, et al. Prognostic factors in stereotactic body radiotherapy for non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2011; 79: 1104-11. doi: http://dx. doi.org/10.1016/j.ijrobp.2009.12.022
34. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45: 228-47. doi: http://dx.doi.org/10.1016/j.ejca.2008.10.026
35. Villaruz LC, Socinski MA. The clinical viewpoint: definitions, limitations of RECIST, practical considerations of measurement. Clin Cancer Res 2013; 19: 2629-36. doi: http://dx. doi.org/10.1158/1078-0432.CCR-12-2935
36. Sharma MR, Maitland ML, Ratain MJ. RECIST: no longer the sharpest tool in the oncology clinical trials toolbox-point. Cancer Res 2012; 72: 5145-9. doi: http://dx.doi.org/10.1158/0008-5472.CAN-12-0058
37. Yoon SH, Kim KW, Goo JM, Kim DW, Hahn S. Observer variability in RECIST-based tumour burden measurements: a meta-analysis. Eur J Cancer 2016; 53: 5-15. doi: http://dx.doi.org/10.1016/j.ejca.2015.10.014
38. Oxnard GR, Zhao B, Sima CS, Ginsberg MS, James LP, Lefkowitz RA, et al. Variability of lung tumor measurements on repeat computed tomography scans taken within 15 minutes. J Clin Oncol 2011; 29: 3114-19. doi: http://dx.doi.org/10.1200/JCO.2010.33.7071
39. Erasmus JJ, Gladish GW, Broemeling L, Sabloff BS, Truong MT, Herbst RS, et al. Interobserver and intraobserver variability in measurement of non-small-cell carcinoma lung lesions: implications for assessment of tumor response. J Clin Oncol 2003; 21: 2574-82. doi: http://dx.doi.org/10.1200/JCO.2003.01.144
40. Huang K, Senthi S, Palma DA, Spoelstra FO, Warner A, Slotman BJ, et al. High-risk CT features for detection of local recurrence after stereotactic ablative radiotherapy for lung cancer. Radiother Oncol 2013; 109: 51-7. doi: http://dx.doi.org/10.1016/j.radonc.2013.06.047
41. Ratain MJ, Eckhardt SG. Phase II studies of modern drugs directed against new targets: if you are fazed, too, then resist RECIST. J Clin Oncol 2004; 22: 4442-5. doi: http://dx.doi.org/10.1200/JCO.2004.07.960
42. Chiou VL, Burotto M. Pseudoprogression and immune-related response in solid tumors. J Clin Oncol 2015; 33: 3541-3. doi: http://dx.doi.org/10.1200/JCO.2015.61.6870
43. Senan S, Palma DA, Lagerwaard FJ. Stereotactic ablative radiotherapy for stage I NSCLC: recent advances and controversies. J Thorac Dis 2011; 3: 189-96. doi: http://dx. doi.org/10.3978/j.issn.2072-1439.2011.05.03
44. Mattonen SA, Palma DA, Haasbeek CJ, Senan S, Ward AD. Early prediction of tumor recurrence based on CT texture changes after stereotactic ablative radiotherapy (SABR) for lung cancer. Med Phys 2014; 41: 033502. doi: http://dx.doi.org/10.1118/1.4866219
45. Mattonen SA, Palma DA, Haasbeek CJ, Senan S, Ward AD. Distinguishing radiation fibrosis from tumour recurrence after stereotactic ablative radiotherapy (SABR) for lung cancer: a quantitative analysis of CT density changes. Acta Oncol 2013; 52: 910-18. doi: http://dx. doi.org/10.3109/0284186X.2012.731525
46. Mattonen SA, Palma DA, Johnson C, Louie AV, Landis M, Rodrigues G, et al. Detection of local cancer recurrence after stereotactic ablative radiotherapy (SABR) for lung cancer: physician performance versus radiomic assessment. Int J Radiat Oncol Biol Phys 2016; 94: 1121-8. doi: http://dx.doi.org/10.1016/j.ijrobp.2015.12.369
47. Daly ME, Beckett LA, Chen AM. Does early posttreatment surveillance imaging affect subsequent management following stereotactic body radiation therapy for early-stage non-small cell lung cancer? Pract Radiat Oncol 2014; 4: 240-6. doi: http://dx.doi.org/10.1016/j.prro.2013.08.006
48. Huang K, Dahele M, Senan S, Guckenberger M, Rodrigues GB, Ward A, et al. Radiographic changes after lung stereotactic ablative radiotherapy (SABR)-can we distinguish recurrence from fibrosis? A systematic review of the literature. Radiother Oncol 2012; 102: 335-42. doi: http://dx.doi.org/10.1016/j.radonc.2011.12.018
49. Peulen H, Mantel F, Guckenberger M, Belderbos J, Werner-Wasik M, Hope A, et al. Validation of high risk CT features for detection of local recurrence after stereotactic body radiotherapy for early stage non-small cell lung cancer. Int J Radiat Oncol Biol Phys 2016. doi: http://dx.doi.org/10.1016/j. ijrobp.2016.04.003
50. Halpenny D, Ridge CA, Hayes S, Zheng J, Moskowitz CS, Rimner A, et al. Computed tomographic features predictive of local recurrence in patients with early stage lung cancer treated with stereotactic body radiation therapy. Clin Imaging 2015; 39: 254-8. doi: http://dx.doi.org/10.1016/j. clinimag.2014.12.005
51. Zhang J, Yang F, Li B, Li H, Liu J, Huang W, et al. Which is the optimal biologically effective dose of stereotactic body radiotherapy for stage I non-small-cell lung cancer? A meta-analysis. Int J Radiat Oncol Biol Phys 2011; 81: e305-16. doi: http://dx.doi.org/10.1016/j.ijrobp.2011.04.034
52. Dunlap NE, Larner JM, Read PW, Kozower BD, Lau CL, Sheng K, et al. Size matters: a comparison of T1 and T2 peripheral nonsmall-cell lung cancers treated with stereotactic body radiation therapy (SBRT). J Thorac Cardiovasc Surg 2010; 140: 583-9. doi: http://dx.doi.org/10.1016/j.jtcvs.2010.01.046
53. Lambin P, Rios-Velazquez E, Leijenaar R, Carvalho S, van Stiphout RG, Granton P, et al. Radiomics: extracting more information from medical images using advanced feature analysis. Eur J Cancer 2012; 48: 441-6. doi: http://dx.doi.org/10.1016/j. ejca.2011.11.036
54. Gillies RJ, Kinahan PE, Hricak H. Radiomics: images are more than pictures, they are data. Radiology 2015; 278: 151169. doi: http://dx. doi.org/10.1148/radiol.2015151169
55. Kim H, Park CM, Goo JM, Wildberger JE, Kauczor HU. Quantitative computed tomography imaging biomarkers in the diagnosis and management of lung cancer. Invest Radiol 2015; 50: 571-83. doi: http://dx. doi.org/10.1097/RLI.0000000000000152
56. Alobaidli S, McQuaid S, South C, Prakash V, Evans P, Nisbet A. The role of texture analysis in imaging as an outcome predictor and potential tool in radiotherapy treatment planning. Br J Radiol 2014; 87: 20140369. doi: http://dx.doi.org/10.1259/bjr.20140369
57. Aerts HJ, Velazquez ER, Leijenaar RT, Parmar C, Grossmann P, Cavalho S, et al. Decoding tumour phenotype by noninvasive imaging using a quantitative radiomics approach. Nat Commun 2014; 5: 4006. doi: http://dx.doi.org/10.1038/ncomms5006
58. Haralick RM. Statistical and structural approaches to texture. Proc IEEE 1979; 67: 786-804. doi: http://dx.doi.org/10.1109/PROC.1979.11328
59. Haralick RM, Shanmugam K, Dinstein I. Textural features for image classification. IEEE Trans Syst Man Cybernet 1973; 3: 610-21. doi: http://dx.doi.org/10.1109/TSMC.1973.4309314
60. Galloway MM. Texture analysis using gray level run lengths. Comput Graph Image Processing 1975; 4: 172-9. doi: http://dx.doi.org/10.1016/S0146-664X(75)80008-6
61. Castellano G, Bonilha L, Li LM, Cendes F. Texture analysis of medical images. Clin Radiol 2004; 59: 1061-9. doi: http://dx.doi.org/10.1016/j.crad.2004.07.008
62. Lindblad J. Surface area estimation of digitized 3D objects using weighted local configurations. Image Vis Comput 2005; 23: 111-22. doi: http://dx.doi.org/10.1016/j.imavis.2004.06.012
63. Grove O, Berglund AE, Schabath MB, Aerts HJ, Dekker A, Wang H, et al. Quantitative computed tomographic descriptors associate tumor shape complexity and intratumor heterogeneity with prognosis in lung adenocarcinoma. PLoS One 2015; 10: e0118261. doi: http://dx.doi.org/10.1371/journal.pone.0118261
64. Defraene G, van Elmpt W, Crijns W, Slagmolen P, De Ruysscher D. CT characteristics allow identification of patient-specific susceptibility for radiation-induced lung damage. Radiother Oncol 2015; 117: 29-35. doi: http://dx.doi.org/10.1016/j.radonc.2015.07.033
65. Ghobadi G, Wiegman EM, Langendijk JA, Widder J, Coppes RP, van Luijk P. A new CTbased method to quantify radiation-induced lung damage in patients. Radiother Oncol 2015; 117: 4-8. doi: http://dx.doi.org/10.1016/j.radonc.2015.07.017
66. Cunliffe A, Armato SG, Castillo R, Pham N, Guerrero T, Al-Hallaq HA. Lung texture in serial thoracic computed tomography scans: correlation of radiomics-based features with radiation therapy dose and radiation pneumonitis development. Int J Radiat Oncol Biol Phys 2015; 91: 1048-56. doi: http://dx.doi.org/10.1016/j.ijrobp.2014.11.030
67. Krafft S, Briere T, Court L, Martel M. TUCD-BRB-01: normal lung CT texture features improve predictive models for radiation pneumonitis. Med Phys 2015; 42: 3602. doi: http://dx.doi.org/10.1118/1.4925586
68. De Ruysscher D, Sharifi H, Defraene G, Kerns SL, Christiaens M, De Ruyck K, et al. Quantification of radiation-induced lung damage with CT scans: the possible benefit for radiogenomics. Acta Oncol 2013; 52: 1405-10. doi: http://dx.doi.org/10.3109/0284186X.2013.813074
69. Burdick MJ, Stephans KL, Reddy CA, Djemil T, Srinivas SM, Videtic GM. Maximum standardized uptake value from staging FDG-PET/CT does not predict treatment outcome for early-stage non-small-cell lung cancer treated with stereotactic body radiotherapy. Int J Radiat Oncol Biol Phys 2010; 78: 1033-9. doi: http://dx.doi.org/10.1016/j.ijrobp.2009.09.081
70. Takeda A, Kunieda E, Fujii H, Yokosuka N, Aoki Y, Oooka Y, et al. Evaluation for local failure by 18F-FDG PET/CT in comparison with CT findings after stereotactic body radiotherapy (SBRT) for localized non-smallcell lung cancer. Lung Cancer 2013; 79: 248-53. doi: http://dx.doi.org/10.1016/j. lungcan.2012.11.008
71. Satoh Y, Nambu A, Onishi H, Sawada E, Tominaga L, Kuriyama K, et al. Value of dual time point F-18 FDG-PET/CT imaging for the evaluation of prognosis and risk factors for recurrence in patients with stage I nonsmall cell lung cancer treated with stereotactic body radiation therapy. Eur J Radiol 2012; 81: 3530-4. doi: http://dx.doi.org/10.1016/j.ejrad.2011.11.047
72. Kohutek ZA, Wu AJ, Zhang Z, Foster A, Din SU, Yorke ED, et al. FDG-PET maximum standardized uptake value is prognostic for recurrence and survival after stereotactic body radiotherapy for non-small cell lung cancer. Lung Cancer 2015; 89: 115-20. doi: http://dx. doi.org/10.1016/j.lungcan.2015.05.019
73. Takeda A, Yokosuka N, Ohashi T, Kunieda E, Fujii H, Aoki Y, et al. The maximum standardized uptake value (SUVmax) on FDGPET is a strong predictor of local recurrence for localized non-small-cell lung cancer after stereotactic body radiotherapy (SBRT). Radiother Oncol 2011; 101: 291-7. doi: http://dx.doi.org/10.1016/j.radonc.2011.08.008
74. Zhang X, Liu H, Balter P, Allen PK, Komaki R, Pan T, et al. Positron emission tomography for assessing local failure after stereotactic body radiotherapy for non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2012; 83: 1558-65. doi: http://dx.doi.org/10.1016/j.ijrobp.2011.10.035
75. Nakajima N, Sugawara Y, Kataoka M, Hamamoto Y, Ochi T, Sakai S, et al. Differentiation of tumor recurrence from radiation-induced pulmonary fibrosis after stereotactic ablative radiotherapy for lung cancer: characterization of 18F-FDG PET/CT findings. Ann Nucl Med 2013; 27: 261-70. doi: http://dx.doi.org/10.1007/s12149-012-0682-4
76. Essler M, Wantke J, Mayer B, Scheidhauer K, Bundschuh RA, Haller B, et al. Positronemission tomography CT to identify local recurrence in stage I lung cancer patients 1 year after stereotactic body radiation therapy. Strahlenther Onkol 2013; 189: 495-501. doi: http://dx.doi.org/10.1007/s00066-013-0310-9
77. Bollineni VR, Widder J, Pruim J, Langendijk JA, Wiegman EM. Residual (1)(8)F-FDG-PET uptake 12 weeks after stereotactic ablative radiotherapy for stage I non-small-cell lung cancer predicts local control. Int J Radiat Oncol Biol Phys 2012; 83: e551-5. doi: http://dx.doi.org/10.1016/j.ijrobp.2012.01.012
78. Clarke K, Taremi M, Dahele M, Freeman M, Fung S, Franks K, et al. Stereotactic body radiotherapy (SBRT) for non-small cell lung cancer (NSCLC): is FDG-PET a predictor of outcome? Radiother Oncol 2012; 104: 62-6. doi: http://dx.doi.org/10.1016/j. radonc.2012.04.019
79. Henderson MA, Hoopes DJ, Fletcher JW, Lin PF, Tann M, Yiannoutsos CT, et al. A pilot trial of serial 18F-fluorodeoxyglucose positron emission tomography in patients with medically inoperable stage I non-small-cell lung cancer treated with hypofractionated stereotactic body radiotherapy. Int J Radiat Oncol Biol Phys 2010; 76: 789-95. doi: http://dx.doi.org/10.1016/j.ijrobp.2009.02.051
80. Matsuo Y, Nakamoto Y, Nagata Y, Shibuya K, Takayama K, Norihisa Y, et al. Characterization of FDG-PET images after stereotactic body radiation therapy for lung cancer. Radiother Oncol 2010; 97: 200-4. doi: http://dx.doi.org/10.1016/j.radonc.2010.04.011
81. Boellaard R. Need for standardization of 18FFDG PET/CT for treatment response assessments. J Nucl Med 2011; 52(Suppl. 2): 93S-100. doi: http://dx.doi.org/10.2967/jnumed.110.085662
82. Leijenaar RT, Nalbantov G, Carvalho S, van Elmpt WJ, Troost EG, Boellaard R, et al. The effect of SUV discretization in quantitative FDG-PET radiomics: the need for standardized methodology in tumor texture analysis. Sci Rep 2015; 5: 11075. doi: http://dx.doi.org/10.1038/srep11075
83. Sawyer B, Pun E, Samuel M, Tay H, Kron T, Bressel M, et al. CT perfusion imaging in response assessment of pulmonary metastases undergoing stereotactic ablative radiotherapy. J Med Imaging Radiat Oncol 2015; 59: 207-15. doi: http://dx.doi.org/10.1111/1754-9485.12272
84. Moore W, Chaya Y, Chaudhry A, Depasquale B, Glass S, Lee S, et al. Computed tomography assessment of ablation zone enhancement in patients with early-stage lung cancer after stereotactic ablative radiotherapy. J Comput Assist Tomogr 2015; 39: 804-9. doi: http://dx.doi.org/10.1097/RCT.0000000000000262